enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Purchases 41,639 Shares

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the acquisition, the insider now directly owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Stock Performance

ENGN opened at $9.02 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The company has a market cap of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The stock has a 50-day moving average of $6.71 and a 200-day moving average of $9.68. enGene Holdings Inc. has a 52-week low of $4.42 and a 52-week high of $43.00.

enGene (NASDAQ:ENGN) last announced its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, equities research analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in enGene during the first quarter valued at about $17,095,000. SR One Capital Management LP bought a new position in shares of enGene in the second quarter worth about $4,715,000. Logos Global Management LP lifted its position in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in enGene during the 1st quarter valued at approximately $2,039,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ENGN. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene presently has an average rating of “Buy” and a consensus target price of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.